Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia

Ann Hematol. 2020 May;99(5):1141-1143. doi: 10.1007/s00277-020-03976-w. Epub 2020 Mar 7.

Authors

Miao Chen¹, Junling Zhuang¹, Chen Yang¹, Lu Zhang¹, Wei Wang¹, Huacong Cai¹, Yanfang Yu², Jian Li¹, Daobin Zhou¹, Bing Han³

Affiliations

¹ Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100730, China.
² Department of Hematology, Peking University Shougang Hospital, Beijing, 100144, China.
³ Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, 100730, China. hanbingpumch@163.com.

PMID: 32144437
DOI: 10.1007/s00277-020-03976-w

No abstract available

Publication types

Letter

MeSH terms

Anemia, Hemolytic, Autoimmune / diagnosis
Anemia, Hemolytic, Autoimmune / drug therapy*
Anemia, Hemolytic, Autoimmune / immunology
Bortezomib / administration & dosage*
Drug Resistance
Drug Therapy, Combination
Humans
Molecular Targeted Therapy
Retreatment
Rituximab / administration & dosage*
Treatment Outcome

Substances

Rituximab
Bortezomib

Grants and funding